Background: Pancreatectomy offers only potential for cure but is only possible in a minority of pts. Even in those pts who receive adjuvant C, majority of them succumb to death due to metastases. RTOG 9704 showed that post-surgery CA 19-9 levels are an important predictor of survival. ESPAC-3 showed that completion of all 6 cycles of adjuvant C was an independent prognostic factor. Any survival benefit of an intensified C strategy has not been demonstrated in pts with persistently ↑ CA19-9. The object of this study was to investigate any benefit of additional C following adjuvant in these pts. Methods: 25 pts with R₀ surgery of PC who received adjuvant C with post-surgery ↑ CA 19-9 but no radiographic evidence of cancer were identified between 2005-2017. Either biopsy or PET scan determined recurrence of PC. Efficacy endpoints were overall survival (OS) and disease-free survival (DFS). Results: The Table summarizes results. Additional C included 5-FU, capecitabine, platins, irinotecan and nab-paclitaxel. CA 19-9 normalized in 3 pts while 22 remained ↑ or further ↑. Two pts underwent metastatectomy. Median DFS was 14.5m (9-18), OS 29m (19-96) and OS rates were 80 %, 50 % at 1 and 2 years respectively. Conclusions: We believe that the longer OS of our pts with ↑ CA 19-9 post-surgery was due to additional C following adjuvant C, close monitoring with monthly CA19-9 and 3-monthly CT scans. Our study also underlines importance of collecting pre-surgery CA19-9 and complete staging including chest. Prospective study aiming to evaluate role of maintenance or intensified C are indicated.